Amino acid transporter PET/CT imaging with MET/FET for AATS-related tumors
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
This project tries PET/CT scans using 11C- or 18F-labeled MET/FET tracers to see if they better find primary or metastatic lesions in adults with amino acid transporter–related tumors such as glioma and primary hyperparathyroidism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 2 sites (Hefei, Anhui and 1 other locations) |
| Trial ID | NCT07379463 on ClinicalTrials.gov |
What this trial studies
This observational study enrolls adult patients with AATS-related diseases who are undergoing PET/CT with 11C- or 18F-MET/FET for initial assessment or for detection of recurrence. Lesion uptake is measured quantitatively using maximum standardized uptake value (SUVmax). Imaging results are compared with available clinical reference standards (for example MRI, CT, pathology, or tumor markers). The study reports diagnostic performance metrics including sensitivity, specificity, positive and negative predictive values, and overall accuracy.
Who should consider this trial
Good fit: Adults (age ≥18) with suspected, newly diagnosed, or previously treated malignant tumors linked to the amino acid transporter system (for example glioma or primary hyperparathyroidism) who are scheduled for an AATS PET/CT and can provide informed consent.
Not a fit: Patients with non-malignant lesions, pregnant individuals, or anyone unable or unwilling to provide written informed consent are not expected to receive benefit from this imaging protocol.
Why it matters
Potential benefit: If successful, these tracers could help clinicians locate and characterize primary and metastatic AATS-related tumors more accurately, improving treatment planning and follow-up.
How similar studies have performed: Amino-acid PET tracers such as 11C-MET and 18F-FET have shown promising diagnostic performance—especially in glioma imaging—while their application across other AATS-related conditions is less well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. adult patients (aged 18 years or order); 2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); 3. patients who had scheduled AATS PET/CT scan; 4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. patients with non-malignant lesions; 2. patients with pregnancy; 3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Hefei, Anhui and 1 other locations
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (Recruiting)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.